Qube Research & Technologies LTD Coherus Bio Sciences, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$1.59 - $3.85 $928,036 - $2.25 Million	583,671 New	583,671 $1.94 Million
Q2 2022 Aug 15, 2022	BUY	$5.86 - $13.23 $507,188 - $1.15 Million	86,551 New	86,551 $627,000
Q1 2022 May 09, 2022	SELL	$10.92 - $16.41 $441,015 - $662,734	-40,386 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$15.81 - $18.99 $638,502 - $766,930	40,386 New	40,386 $645,000
Q3 2020 Nov 12, 2020	SELL	$17.41 - $19.89 $271,369 - $310,025	-15,587 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$14.43 - $19.16 $14,603 - $19,389	1,012 Added 6.94%	15,587 $278,000
Q1 2020 May 15, 2020	BUY	$11.67 - $22.53 $170,090 - $328,374	14,575 New	14,575 $236,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $122M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.